Nial J. Wheate

Multi-nuclear platinum complexes encapsulated in cucurbit[n]uril as an approach to reduce toxicity in cancer treatment.

Potential adenine and minor groove binding platinum complexes.

Multi-nuclear platinum drugs: a new paradigm in chemotherapy.

Cucurbit[n]uril binding of platinum anticancer complexes.

Polyamide platinum anticancer complexes designed to target specific DNA sequences.

Synthesis of DNA-sequence-selective hairpin polyamide platinum complexes.

The effect of ancillary ligand chirality and phenanthroline functional group substitution on the cytotoxicity of platinum(II)-based metallointercalators.

DNA intercalators in cancer therapy: organic and inorganic drugs and their spectroscopic tools of analysis.

Encapsulation of platinum(II)-based DNA intercalators within cucurbit[6,7,8]urils.

Novel platinum(II)-based anticancer complexes and molecular hosts as their drug delivery vehicles.

Examination of cucurbit[7]uril and its host-guest complexes by diffusion nuclear magnetic resonance.

Degradation of bidentate-coordinated platinum(II)-based DNA intercalators by reduced L-glutathione.

Substituted beta-cyclodextrin and calix[4]arene as encapsulatory vehicles for platinum(II)-based DNA intercalators.

Improving platinum(II)-based anticancer drug delivery using cucurbit[n]urils.

Anionic PAMAM dendrimers as drug delivery vehicles for transition metal-based anticancer drugs.

Side-on binding of p-sulphonatocalix[4]arene to the dinuclear platinum complex trans-[{PtCl(NH3)2}2mu-dpzm]2+ and its implications for anticancer drug delivery.

Diffusion-based studies on the self-stacking and nanorod formation of platinum(II) intercalators.

Studies of the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells.

A chemical preformulation study of a host-guest complex of cucurbit[7]uril and a multinuclear platinum agent for enhanced anticancer drug delivery.

Solid state stabilisation of the orally delivered drugs atenolol, glibenclamide, memantine and paracetamol through their complexation with cucurbit[7]uril.

Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin.

The status of platinum anticancer drugs in the clinic and in clinical trials.

Synthesis, processing and solid state excipient interactions of cucurbit[6]uril and its formulation into tablets for oral drug delivery.

Microwave synthesis of cucurbit[n]urils.

Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin.

Cisplatin-tethered gold nanoparticles that exhibit enhanced reproducibility, drug loading, and stability: a step closer to pharmaceutical approval?

Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect.

Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity.

Nanoparticles: the future for platinum drugs or a research red herring?

DNA-based aptamer fails as a simultaneous cancer targeting agent and drug delivery vehicle for a phenanthroline-based platinum(II) complex.

Topical cream-based dosage forms of the macrocyclic drug delivery vehicle cucurbit[6]uril.

A cisplatin slow-release hydrogel drug delivery system based on a formulation of the macrocycle cucurbit[7]uril, gelatin and polyvinyl alcohol.